|
 Mild Cognitive Impairment
 Merz - our research for your health. Recent results from a Phase III trial show that patients receiving a combination of memantine and donepezil performed significantly better than patients receiving donepezil and placebo.
Mild Cognitive Impairment: learn more about the different forms of diseases, current research, drugs, treatment, therapies and care. Mild Cognitive Impairment is a topic that anyone of us should think about, because when growing old, everyone could be affected. Inform yourself about Mild Cognitive Impairment now! The care for elderly people and their diseases are a topic for our society, whose importance grows each day. That's why we at Merz take Mild Cognitive Impairment very serious, so that we can offer you the best drug for each treatment and therapy you need. Mild Cognitive Impairment and Merz means research for your health. High-quality products and information about Mild Cognitive Impairment can be found on our website. Visit us online and learn everything about Mild Cognitive Impairment from one of Germany's leading health care companies. Our contribution to Mild Cognitive Impairment: read here what we can do for you. Further links: Axura: Information for professionals.>>>
The care for elderly people and their diseases are a topic for our society, whose importance grows each day.
Memantine , Alzheimer's Treatment . Calcium enters into the cell, and through secondary processes, the signal is recognized. Such excitotoxicity ultimately leads to neuronal calcium overload and has been implicated in neurodegenerative disorders. Senile Dementia , Dementia Care . A signal is produced which due to the lower noise can be recognized and processed which leads to a symptomatic improvement in dementia symptoms. The starting point is the pathological release of glutamate, followed by elevated calcium concentrations. Alzheimer's Research , Alzheimer . Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. In the case of learning and memory processes, the transient synaptic release of glutamate causes more calcium to flow into the cell. During learning and memory processes (i e transient high glutamate release), memantine - the fast, voltage-dependent NMDA-receptor antagonist - leaves the NMDA receptor for a short time. At the same time, Memantine reduces caregiver time by more than 50 hours a month. A signal is produced which due to the lower noise can be recognized and processed which leads to a symptomatic improvement in dementia symptoms. Demenzkranke , Verwirrtheit Gedächtnisstörungen Short Term Memory Loss Symptoms Of Alzheimer's Disease . If you have questions regarding Memantine, Axura or Namenda, please contact the responsible department. Alzheimer Erkrankung , Symptoms Of Alzheimer's Alzheimer's Disease Symptoms . The excitatory neurotransmitter glutamate plays an important part in the development of neurodegenerative diseases like dementia. Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Glutamate is the principal neurotransmitter in the brain. In studies of memantine, doctors assessed tolerability as good or very good in 93 percent of patients. Alzheimer's Drug Dementia Symptoms , Hirnleistungsstörungen . About 70 percent of all excitatory synapses in the central nervous system are stimulated by the neurotransmitter glutamate. Memantine is a NMDA receptor antagonist and protects the glutamatergic system from pathological activation. Clinically-relevant doses of memantine produce improvements in learning under conditions of tonic NMDA receptor activation in Alzheimer's disease. Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. Demenz Krankheit Alzheimer Behandlung NMDA-Schutz Demenz Früherkennung , Mild Cognitive Impairment Altersdemenz . However, due to the already elevated calcium concentration, the signal can no longer be detected (occurrence of dementia symptoms). In studies of memantine, doctors assessed tolerability as good or very good in 93 percent of patients. The starting point is the pathological release of glutamate, followed by elevated calcium concentrations. Merz Pharmaceuticals, as a member of Merz Pharma, is an innovative and international healthcare company, specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. The safety of the combination therapy was investigated in a postmarketing surveillance study. Alzheimer und Demenz , Glutamate Demenz Behandlung Demenz-Erkrankung . Other franchise covered by Merz are hepatology, metabolic diseases and dermatology. Under physiological conditions, the NMDA receptor is blocked by magnesium ions, thereby protecting the neuron against glutamatergic excitotoxicity. Dysfunction of glutamatergic neurotransmission is involved in pathomechanism of neurodegenerative dementia. Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Alzheimer's Disease Alzheimer Therapie , Symptoms Of Dementia . If you have questions regarding Memantine, Axura or Namenda, please contact the responsible department. NMDA-Antagonist Forgetfulness , Glutamat Alzheimer Früherkennung . There is a continuous influx of calcium into the cell, increasing the calcium pool. vaskuläre Demenz , Lewy Body Dementia Demenz Therapie Vascular Dementia . Calcium enters into the cell, and through secondary processes, the signal is recognized. Gedächtnis , Demenz . The pathological, sustained release of low glutamate concentrations, from both neurones and surrounding glia cells, also displaces magnesium from the NMDA receptor channel. Merz , Multi Infarct Dementia . In the case of learning and memory processes, the transient synaptic release of glutamate causes more calcium to flow into the cell. Alzheimer's Dementia Axura , Vergesslichkeit Antidementiva Alzheimer's Caregiver . Stages Of Alzheimer's Disease , Akatinol Alzheimer's Support Hirnleistungsstörung NMDA-Protection . Due to its strong voltage-dependency, magnesium leaves the NMDA receptor. Alzheimer's , Demenzerkrankung Dementia . Memantine is a NMDA receptor antagonist and protects the glutamatergic system from pathological activation. Clinically-relevant doses of memantine produce improvements in learning under conditions of tonic NMDA receptor activation in Alzheimer's disease. Memory Loss Pseudodemenz Alzheimer's Care , Dementia Treatment . Memantine is the first representative of a new class of Alzheimer drugs, a moderate affinity NMDA-receptor antagonist. Dementia And Alzheimer's Alzheimer Krankheit , Demenzkrank . Due to its strong voltage-dependency, magnesium leaves the NMDA receptor. Alzheimer's Symptoms , Mental Confusion . Memantine improves cognitive and psychomotor functioning, activities in daily living and the clinical global impression. Glutamate is the principal neurotransmitter in the brain. Dementia Medication Literatur , Erkennung Diagnose Studien . In contrast to first generation therapies, Memantine is likely to show neuroprotective effects at concentrations used in the treatment of Alzheimer s disease and to slow down disease progression. Memantine is well tolerated even in long-term therapy. Memantine is well tolerated even in long-term therapy. Memantine is well tolerated even in long-term therapy. Medikamentkombinationen , Demenz Medikament . The excitatory effect of chronically released glutamate effects the degeneration of cortical and subcortical neurons, thus leading to the occurrence of dementia symptoms. Therapy , Help . Diagnosis , Information Literature . Studies , Combination . Treatment Alzheimer's Therapie Demenz Alzheimer Medikament , Medication Alzheimer's .
 Mild Cognitive Impairment
|
